Senseonics (NYSE:SENS) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Senseonics (NYSE:SENS - Get Free Report) in a note issued to investors on Wednesday. The firm set a "sell" rating on the stock.

Separately, HC Wainwright restated a "buy" rating and set a $2.00 target price on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

NYSE:SENS traded down $0.01 during mid-day trading on Wednesday, reaching $0.41. The stock had a trading volume of 9,521,813 shares, compared to its average volume of 3,669,286. The stock has a market capitalization of $241.70 million, a P/E ratio of -3.12 and a beta of 0.77. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics has a one year low of $0.25 and a one year high of $0.75. The firm has a 50 day moving average price of $0.33 and a two-hundred day moving average price of $0.37.

Insiders Place Their Bets

In related news, CFO Frederick T. Sullivan bought 124,933 shares of the business's stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares of the company's stock, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the business's stock in a transaction on Tuesday, December 10th. The stock was purchased at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company's stock, valued at approximately $3,506,210.05. The trade was a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Institutional Trading of Senseonics

A number of institutional investors and hedge funds have recently made changes to their positions in SENS. FMR LLC grew its stake in Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after acquiring an additional 167,970 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Senseonics during the third quarter worth $117,000. Symmetry Partners LLC purchased a new stake in Senseonics in the third quarter valued at $164,000. Cubist Systematic Strategies LLC lifted its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock valued at $166,000 after purchasing an additional 85,501 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock worth $2,042,000 after purchasing an additional 179,103 shares during the period. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.